Filter posts

UK Bioscience Forum: Confronting Common Challenges

This week, BIO’s President and CEO Jim Greenwood delivered a plenary address to attendees at …

Crowdfunding in Health Care and Biotechnology

Smaller private companies are constantly in search of capital, but many find it difficult to …

Confused Consumers are a Desirable Bonus of I-522

With less than a month out, Washington State Initiative 522 continues to garner more and …

The New Road to IPO in the Age of the JOBS Act

Not surprisingly, sessions discussing the topic of IPOs at this year’s BIO Investor Forum, tend …

BIO Patient and Health Advocacy Summit: Patient-Focused Drug Development

Panelists in this morning’s opening session outlined strategies for the FDA to better engage the …

The "Designer Baby" Patent: Why the Patent System Should Not Regulate Science

23andMe received criticism this week from a few bioethicists in the journal Genetics in Medicine, …

Biotech IPO Boom or Bubble? The Opening Plenary at the BIO Investor Forum

With 31 (and counting) life sciences companies having already placed IPOs on the market within …

Successful Public-Private Partnerships

According to BayBio, biomedical companies that can harness the power of patient groups will get …

JOBS Act Deconstructed: Regulation A

More than 40 biotech companies have gone public using provisions made available to emerging growth …

BIO Investor Forum Kicks Off Amid Industry Optimism

Today, the BIO Investor Forum kicks off in San Francisco, Calif. BioWorld’s Catherine Shaffer paints …